

Lars Bullinger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5215189/lars-bullinger-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 306 papers | 22,571 citations | 67 h-index | 148 g-index |
| 330 ext. papers | 26,762 ext. citations | 7.4 avg, IF | 6.26 L-index |

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 306 | Acute left ventricular insufficiency in a Burkitt Lymphoma patient with myocardial involvement and extensive local tumor cell lysis: a case report.. <i>BMC Cardiovascular Disorders</i> , 2022 , 22, 31 | 2.3 | 0 |
| 305 | Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.. <i>Nature Communications</i> , 2022 , 13, 1009 | 17.4 | 3 |
| 304 | EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.. <i>Frontiers in Immunology</i> , 2022 , 13, 877477 | 8.4 | 0 |
| 303 | FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.. <i>BMC Cancer</i> , 2022 , 22, 359 | 4.8 | |
| 302 | Antigen presentation safeguards the integrity of the hematopoietic stem cell pool.. <i>Cell Stem Cell</i> , 2022 , 29, 760-775.e10 | 18 | 1 |
| 301 | Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort. <i>Frontiers in Oncology</i> , 2021 , 11, 772809 | 5.3 | 0 |
| 300 | Targeting Control of Cell Cycle Enhances the Activity of Conventional Chemotherapy in Chemotherapy-Resistant Acute Myeloid Leukemia. <i>Blood</i> , 2021 , 138, 2241-2241 | 2.2 | |
| 299 | CTNI-04. RECURRENT GLIOBLASTOMA LONG-TERM SURVIVORS TREATED WITH CUSP9v3. <i>Neuro-Oncology</i> , 2021 , 23, vi59-vi59 | 1 | 1 |
| 298 | Flow Cytometric Analysis of Microbial Diversity in Patients with Aggressive Lymphoma Disease Undergoing Chemoimmunotherapy. <i>Blood</i> , 2021 , 138, 4005-4005 | 2.2 | |
| 297 | The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL. <i>Blood</i> , 2021 , 138, 3852-3852 | 2.2 | 0 |
| 296 | Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021 , 138, 4041-4041 | 2.2 | 0 |
| 295 | PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. <i>Blood</i> , 2021 , | 2.2 | 1 |
| 294 | Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib. <i>HemaSphere</i> , 2021 , 5, e514 | 0.3 | |
| 293 | Endothelial damage and dysfunction in acute graft-versus-host disease. <i>Haematologica</i> , 2021 , 106, 2147-2160 | 2.6 | 5 |
| 292 | Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges. <i>International Journal of Cancer</i> , 2021 , 148, 3097-3110 | 7.5 | 1 |
| 291 | Precision medicine in myeloid malignancies. <i>Seminars in Cancer Biology</i> , 2021 , | 12.7 | 5 |
| 290 | Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. <i>Blood Advances</i> , 2021 , 5, 2294-2304 | 7.8 | 8 |

| | | | |
|-----|---|------|----|
| 289 | Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 2391-2402 | 7.8 | 4 |
| 288 | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab075 | 0.9 | 8 |
| 287 | Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021 , 137, 3093-3104 | 2.2 | 19 |
| 286 | 58/w mit zunehmender psychomotorischer Verlangsamung und Zephalgien. <i>Onkologe</i> , 2021 , 27, 79-84 | 0.1 | |
| 285 | Netboost: Boosting-Supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntington's Disease. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2021 , 18, 2635-2648 | 3 | 1 |
| 284 | Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. <i>Haematologica</i> , 2021 , 106, 446-453 | 6.6 | 11 |
| 283 | Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. <i>Blood</i> , 2021 , 137, 2785-2799 | 2.2 | 7 |
| 282 | Clinical outcome of older adults with acute myeloid Leukemia: An analysis of a large tertiary referral Center over two decades. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 540-549 | 3.6 | 0 |
| 281 | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms. <i>Journal of Pathology: Clinical Research</i> , 2021 , 7, 3-9 | 5.3 | 2 |
| 280 | Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 2688-2692 | 10.7 | 2 |
| 279 | Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2026-2029 | 1.9 | 0 |
| 278 | B cell depletion and signs of sepsis-acquired immunodeficiency in bone marrow and spleen of COVID-19 deceased. <i>International Journal of Infectious Diseases</i> , 2021 , 103, 628-635 | 10.5 | 6 |
| 277 | DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. <i>Genome Research</i> , 2021 , 31, 747-761 | 9.7 | 4 |
| 276 | Deregulated expression of circular RNAs in acute myeloid leukemia. <i>Blood Advances</i> , 2021 , 5, 1490-1503 | 7.8 | 8 |
| 275 | Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. <i>Blood Advances</i> , 2021 , 5, 2707-2716 | 7.8 | 6 |
| 274 | Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2021 , | 10.7 | 4 |
| 273 | Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals. <i>Leukemia and Lymphoma</i> , 2021 , 1-9 | 1.9 | 0 |
| 272 | COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab. <i>PLoS ONE</i> , 2021 , 16, e0255976 | 3.7 | 2 |

| | | | |
|-----|---|------|----|
| 271 | Survivin ^{hi} Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 2 |
| 270 | CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021 , 12, 736137 | 8.4 | |
| 269 | Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021 , 12, 5395 | 17.4 | 1 |
| 268 | Genomic Landscape and Clonal Evolution of AML. <i>Hematologic Malignancies</i> , 2021 , 103-118 | 0 | |
| 267 | Early bilirubinemia after allogeneic stem cell transplantation-an endothelial complication. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1573-1583 | 4.4 | 4 |
| 266 | Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers. <i>Blood</i> , 2020 , 136, 1303-1316 | 2.2 | 31 |
| 265 | Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020 , 135, 2402-2412 | 2.2 | 43 |
| 264 | Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. <i>Trials</i> , 2020 , 21, 437 | 2.8 | 2 |
| 263 | Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2020 , 99, 1551-1560 | 3 | 10 |
| 262 | Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. <i>Blood</i> , 2020 , 136, 1507-1519 | 2.2 | 22 |
| 261 | Functional Classification of Mutations in Acute Myeloid Leukemia. <i>Cancers</i> , 2020 , 12, | 6.6 | 20 |
| 260 | Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Haematologica</i> , 2020 , 105, e264-e267 | 6.6 | 22 |
| 259 | Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia. <i>Science</i> , 2020 , 367, 586-590 | 33.3 | 63 |
| 258 | Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020 , 105, 2440-2447 | 6.6 | 14 |
| 257 | Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience. <i>BMC Cancer</i> , 2020 , 20, 68 | 4.8 | 2 |
| 256 | Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 629-640 | 7.4 | 4 |
| 255 | Clonally Expanded Bone Marrow T Cells Show Effector Differentiation and Rarely Recognize Disease-Associated Antigens in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 7-7 | 2.2 | |
| 254 | Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis) <i>Blood</i> , 2020 , 136, 28-28 | 2.2 | 2 |

| | | | |
|-----|--|------|----|
| 253 | The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia. <i>Haematologica</i> , 2020 , 105, e448-453 | 6.6 | 2 |
| 252 | Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. <i>Haematologica</i> , 2020 , 105, 1379-1390 | 6.6 | 7 |
| 251 | Single-cell analysis based dissection of clonality in myelofibrosis. <i>Nature Communications</i> , 2020 , 11, 73 | 17.4 | 23 |
| 250 | Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia. <i>Haematologica</i> , 2020 , 105, e454-457 | 6.6 | 4 |
| 249 | A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020 , 21, 828 | 2.8 | 7 |
| 248 | Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. <i>Nature</i> , 2020 , 588, 157-163 | 50.4 | 24 |
| 247 | Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients. <i>Scientific Reports</i> , 2020 , 10, 12761 | 4.9 | 9 |
| 246 | Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020 , 136, 3041-3050 | 2.2 | 30 |
| 245 | Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , 2020 , 4, 6342-6352 | 7.8 | 11 |
| 244 | Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). <i>Leukemia</i> , 2020 , 34, 404-415 | 10.7 | 10 |
| 243 | Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML). <i>Leukemia</i> , 2020 , 34, 630-634 | 10.7 | 1 |
| 242 | Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1444-1453 | 21.7 | 16 |
| 241 | Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019 , 134, 1608-1618 | 2.2 | 45 |
| 240 | getITD for FLT3-ITD-based MRD monitoring in AML. <i>Leukemia</i> , 2019 , 33, 2535-2539 | 10.7 | 20 |
| 239 | Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019 , 104, e434-e437 | 6.6 | 81 |
| 238 | IGF1R as druggable target mediating PI3K-inhibitor resistance in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 134, 534-547 | 2.2 | 25 |
| 237 | Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , 2019 , 10, 2031 | 17.4 | 63 |
| 236 | Retroperitoneal Hematoma after Bone Marrow Biopsy: The First Cut Should Not Be the Deepest. <i>Oncology Research and Treatment</i> , 2019 , 42, 283-288 | 2.8 | 3 |

| | | | |
|-----|--|------|-----|
| 235 | New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. <i>International Journal of Molecular Sciences</i> , 2019 , 20, | 6.3 | 54 |
| 234 | Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. <i>Journal of Experimental Medicine</i> , 2019 , 216, 966-981 | 16.6 | 60 |
| 233 | NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. <i>Blood</i> , 2019 , 133, 2305-2319 | 2.2 | 20 |
| 232 | Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib. <i>Sarcoma</i> , 2019 , 2019, 3914232 | 3.1 | 5 |
| 231 | Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer. <i>Onc Immunology</i> , 2019 , 8, e1586409 | 7.2 | 13 |
| 230 | Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019 , 37, 375-385 | 2.2 | 97 |
| 229 | Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. <i>Blood</i> , 2019 , 133, 1766-1777 | 2.2 | 10 |
| 228 | IDH2 inhibition: another piece to the puzzle. <i>Blood</i> , 2019 , 133, 625-626 | 2.2 | 1 |
| 227 | Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. <i>Science Advances</i> , 2019 , 5, eaaw4304 | 14.3 | 13 |
| 226 | Functional Classification of TP53 Mutations in Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2725-2725 | 2.2 | 1 |
| 225 | Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSC). <i>Blood</i> , 2019 , 134, 2740-2740 | 2.2 | |
| 224 | Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction. <i>Blood</i> , 2019 , 134, 4487-4487 ² | | |
| 223 | AML: Negative Prognostic Impact of Early Blast Persistence Can be Overcome By Subsequent Remission Induction. <i>Blood</i> , 2019 , 134, 1324-1324 | 2.2 | |
| 222 | Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis. <i>Blood</i> , 2019 , 134, 469-469 | 2.2 | |
| 221 | Long-Term T Cell Expansion Results in Increased Numbers of Central Memory T Cells with Sustained Functional Properties for Adoptive T Cell Therapy. <i>Blood</i> , 2019 , 134, 1943-1943 | 2.2 | |
| 220 | Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 678-688 | 40 | 207 |
| 219 | Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer. <i>Immunotherapy</i> , 2019 , 11, 1193-1203 | 3.8 | 2 |
| 218 | Cytotoxic Effects of Rabbit Anti-thymocyte Globulin Preparations on Primary Human Thymic Epithelial Cells. <i>Transplantation</i> , 2019 , 103, 2234-2244 | 1.8 | 4 |

| | | | |
|-----|--|------|----|
| 217 | Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019 , 133, 1140-1151 | 2.2 | 61 |
| 216 | Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. <i>Cancer</i> , 2019 , 125, 712-725 | 6.4 | 33 |
| 215 | MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. <i>Leukemia</i> , 2018 , 32, 2152-2166 | 10.7 | 50 |
| 214 | Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756285617753597 | 6.6 | 3 |
| 213 | Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. <i>Leukemia</i> , 2018 , 32, 1908-1919 | 10.7 | 75 |
| 212 | The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function. <i>Leukemia</i> , 2018 , 32, 1211-1221 | 10.7 | 11 |
| 211 | Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML. <i>British Journal of Haematology</i> , 2018 , 183, 822-825 | 4.5 | 11 |
| 210 | FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells. <i>European Journal of Immunology</i> , 2018 , 48, 1248-1250 | 6.1 | 11 |
| 209 | Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2018 , 11, 361-371 | 2.8 | 46 |
| 208 | The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study. <i>Neurosurgical Review</i> , 2018 , 41, 207-219 | 3.9 | 17 |
| 207 | Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. <i>Leukemia</i> , 2018 , 32, 1621-1630 | 10.7 | 53 |
| 206 | UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. <i>Nature Genetics</i> , 2018 , 50, 883-894 | 36.3 | 73 |
| 205 | Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. <i>Blood</i> , 2018 , 132, 1501-1501 | 2.2 | 3 |
| 204 | MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia. <i>Oncotarget</i> , 2018 , 9, 22423-22435 | 3.3 | 1 |
| 203 | Chromothripsis is linked to alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. <i>Haematologica</i> , 2018 , 103, e17-e20 | 6.6 | 31 |
| 202 | Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia. <i>Haematologica</i> , 2018 , 103, 246-255 | 6.6 | 5 |
| 201 | QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi218-vi219 | 1 | 78 |
| 200 | Circular RNAs in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018 , 1087, 215-230 | 3.6 | 29 |

| | | | |
|-----|--|------|-----|
| 199 | Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. <i>Leukemia</i> , 2018 , 32, 2546-2557 | 10.7 | 62 |
| 198 | Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. <i>Blood</i> , 2018 , 132, 2707-2721 | 2.2 | 37 |
| 197 | Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells. <i>Blood</i> , 2018 , 132, 2670-2683 | 2.2 | 26 |
| 196 | Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , 2018 , 132, 1703-1713 | 2.2 | 142 |
| 195 | Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. <i>Blood</i> , 2018 , 132, 67-77 | 2.2 | 38 |
| 194 | Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. <i>Annals of Hematology</i> , 2017 , 96, 559-565 | 3 | 16 |
| 193 | Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017 , 49, 332-340 | 36.3 | 155 |
| 192 | Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. <i>Journal of Clinical Oncology</i> , 2017 , 35, 934-946 | 2.2 | 257 |
| 191 | Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1-4 | 1.9 | 4 |
| 190 | Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis. <i>Journal of Neurology</i> , 2017 , 264, 781-791 | 5.5 | 14 |
| 189 | Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life. <i>World Neurosurgery</i> , 2017 , 102, 383-399 | 2.1 | 10 |
| 188 | Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia. <i>Blood</i> , 2017 , 129, e13-e25 | 2.2 | 24 |
| 187 | Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 2039-2047 | 6.6 | 51 |
| 186 | Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. <i>Oncotarget</i> , 2017 , 8, 7678-7690 | 3.3 | 9 |
| 185 | Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. <i>Haematologica</i> , 2017 , 102, e499-e501 | 6.6 | 19 |
| 184 | The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. <i>Experimental Hematology</i> , 2017 , 55, 76-85.e3 | 3.1 | 3 |
| 183 | MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. <i>Leukemia</i> , 2017 , | 10.7 | 1 |
| 182 | BCAT1 restricts 5mG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. <i>Nature</i> , 2017 , 551, 384-388 | 50.4 | 154 |

| | | | |
|-----|--|------|------|
| 181 | Partitioned learning of deep Boltzmann machines for SNP data. <i>Bioinformatics</i> , 2017 , 33, 3173-3180 | 7.2 | 22 |
| 180 | Novel Treatment Options in Head and Neck Cancer. <i>Oncology Research and Treatment</i> , 2017 , 40, 342-346. | 2.8 | 5 |
| 179 | ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. <i>Neuro-Oncology</i> , 2017 , 19, vi13-vi14 | 1 | 13 |
| 178 | Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2392-2406 | 15.9 | 49 |
| 177 | Analysis of splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. <i>Oncotarget</i> , 2017 , 8, 95163-95175 | 3.3 | 6 |
| 176 | is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair. <i>Oncotarget</i> , 2017 , 8, 95038-95053 | 3.3 | 6 |
| 175 | MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. <i>Experimental Hematology</i> , 2016 , 44, 1166-1171 | 3.1 | 13 |
| 174 | MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses. <i>Haematologica</i> , 2016 , 101, e454-e456 | 6.6 | 5 |
| 173 | The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016 , 48, 1551-1556 | 16.5 | 147 |
| 172 | Personalisierte Medizin in der Hämatologie am Beispiel der akuten myeloischen Leukämie. <i>Medizinische Genetik</i> , 2016 , 28, 435-442 | 0.5 | |
| 171 | Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 2209-2221 | 59.2 | 1999 |
| 170 | Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016 , 22, 792-9 | 50.5 | 217 |
| 169 | Low-grade Glioma Surgery in Intraoperative Magnetic Resonance Imaging: Results of a Multicenter Retrospective Assessment of the German Study Group for Intraoperative Magnetic Resonance Imaging. <i>Neurosurgery</i> , 2016 , 78, 775-86 | 3.2 | 83 |
| 168 | Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. <i>Epigenetics</i> , 2016 , 11, 517-25 | 5.7 | 18 |
| 167 | GiANT: gene set uncertainty in enrichment analysis. <i>Bioinformatics</i> , 2016 , 32, 1891-4 | 7.2 | 4 |
| 166 | The RET Receptor Tyrosine Kinase Promotes Acute Myeloid Leukemia through Protection of FLT3-ITD Mutants from Autophagic Degradation. <i>Blood</i> , 2016 , 128, 2849-2849 | 2.2 | 2 |
| 165 | Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition. <i>Blood</i> , 2016 , 128, 4054-4054 | 2.2 | 2 |
| 164 | Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling. <i>PLoS ONE</i> , 2016 , 11, e0155226 | 3.7 | 5 |

| | | | |
|-----|--|------|-----|
| 163 | Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. <i>Oncotarget</i> , 2016 , 7, 49539-49551 | 3.3 | 10 |
| 162 | VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice. <i>Oncotarget</i> , 2016 , 7, 86889-86901 | 3.3 | 4 |
| 161 | Impact of Distinct Genetic and Epigenetic Aberrations on Survival and Response in Acute Myeloid Leukemia Patients Receiving Epigenetic Therapy. <i>Blood</i> , 2016 , 128, 2839-2839 | 2.2 | |
| 160 | Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML. <i>Blood</i> , 2016 , 128, 2878-2878 | 2.2 | |
| 159 | Integrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information. <i>BMC Bioinformatics</i> , 2016 , 17, 327 | 3.6 | 6 |
| 158 | A 17-gene stemness score for rapid determination of risk in acute leukaemia. <i>Nature</i> , 2016 , 540, 433-437 | 50.4 | 369 |
| 157 | T-lymphoid progenitors - we know what they are, but know not what they may be. <i>EMBO Journal</i> , 2016 , 35, 2383-2385 | 13 | 1 |
| 156 | Lenalidomide induces ubiquitination and degradation of CK1 α in del(5q) MDS. <i>Nature</i> , 2015 , 523, 183-188 | 50.4 | 468 |
| 155 | PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones. <i>Immunity</i> , 2015 , 43, 1075-86 | 32.3 | 155 |
| 154 | Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. <i>British Journal of Haematology</i> , 2015 , 168, 507-10 | 4.5 | 36 |
| 153 | Disease evolution and outcomes in familial AML with germline CEBPA mutations. <i>Blood</i> , 2015 , 126, 1214-23 | 23 | 104 |
| 152 | Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2015 , 137, 2959-70 | 7.5 | 14 |
| 151 | Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. <i>International Journal of Cancer</i> , 2015 , 137, 2083-92 | 7.5 | 14 |
| 150 | ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , 2015 , 100, 324-30 | 6.6 | 67 |
| 149 | Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3A _{mut}) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015 , 126, 226-226 | 2.2 | 3 |
| 148 | Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. <i>Blood</i> , 2014 , 123, 894-904 | 2.2 | 82 |
| 147 | Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. <i>Genome Medicine</i> , 2014 , 6, 34 | 14.4 | 25 |
| 146 | Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. <i>Haematologica</i> , 2014 , 99, 1456-64 | 6.6 | 22 |

| | | | |
|-----|--|------|-----|
| 145 | New avenues for genetics guided therapeutic approaches in AML. <i>Acta Haematologica Polonica</i> , 2014 , 45, 322-329 | 0.4 | 1 |
| 144 | Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. <i>Haematologica</i> , 2014 , 99, e133-5 | 6.6 | 10 |
| 143 | Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. <i>Blood</i> , 2014 , 123, 3247-54 | 2.2 | 352 |
| 142 | Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. <i>Blood</i> , 2014 , 124, 3441-9 | 2.2 | 260 |
| 141 | Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. <i>BMC Genomics</i> , 2014 , 15, 784 | 4.5 | 17 |
| 140 | A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples. <i>BMC Genomics</i> , 2014 , 15, 879 | 4.5 | 5 |
| 139 | Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. <i>Epigenetics</i> , 2014 , 9, 1108-19 | 5.7 | 61 |
| 138 | Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. <i>Blood</i> , 2014 , 123, 2355-66 | 2.2 | 32 |
| 137 | Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. <i>Cell Stem Cell</i> , 2014 , 15, 775-90 | 18 | 56 |
| 136 | SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. <i>Blood</i> , 2014 , 124, 121-33 | 2.2 | 70 |
| 135 | DNA Methylation Abnormalities in Hematopoietic Disorders: Biological Significance and Methodological Approaches 2014 , 107-120 | | |
| 134 | Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression. <i>Experimental Hematology</i> , 2014 , 42, 90-100 | 3.1 | 8 |
| 133 | Expression profiling of leukemia patients: key lessons and future directions. <i>Experimental Hematology</i> , 2014 , 42, 651-60 | 3.1 | 33 |
| 132 | GP130 activation induces myeloma and collaborates with MYC. <i>Journal of Clinical Investigation</i> , 2014 , 124, 5263-74 | 15.9 | 27 |
| 131 | Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1172-81 | 2.2 | 112 |
| 130 | Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , 2013 , 121, 4769-77 | 2.2 | 129 |
| 129 | Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3557-64 | 2.2 | 39 |
| 128 | Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. <i>Blood</i> , 2013 , 122, 100-8 | 2.2 | 204 |

127 Leukemias **2013**, 675-690

| | | | |
|-----|---|------|-----|
| 126 | SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. <i>Nature Cell Biology</i> , 2013 , 15, 72-81 | 23.4 | 60 |
| 125 | PBX3 is an important cofactor of HOXA9 in leukemogenesis. <i>Blood</i> , 2013 , 121, 1422-31 | 2.2 | 93 |
| 124 | The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2013 , 133, 1489-96 | 7.5 | 37 |
| 123 | The cell fate determinant Llg1 influences HSC fitness and prognosis in AML. <i>Journal of Experimental Medicine</i> , 2013 , 210, 15-22 | 16.6 | 40 |
| 122 | Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays. <i>Genetic Testing and Molecular Biomarkers</i> , 2013 , 17, 295-300 | 1.6 | 4 |
| 121 | PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17). <i>Clinical Cancer Research</i> , 2013 , 19, 2562-71 | 12.9 | 29 |
| 120 | Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2013 , 121, 170-7 | 2.2 | 134 |
| 119 | The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. <i>Blood</i> , 2013 , 122, 1576-82 | 2.2 | 115 |
| 118 | HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. <i>Haematologica</i> , 2013 , 98, 1216-25 | 6.6 | 27 |
| 117 | CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR δ signaling. <i>Journal of Clinical Investigation</i> , 2013 , 123, 299-314 | 15.9 | 38 |
| 116 | CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. <i>Oncotarget</i> , 2013 , 4, 1438-48 | 3.3 | 18 |
| 115 | Analysis Of Leukemic Stem Cell Population Comparing NPM1wt and NPM1mut AML Patients and Potential Therapeutic Targets. <i>Blood</i> , 2013 , 122, 2624-2624 | 2.2 | |
| 114 | The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2563-2563 | 2.2 | |
| 113 | Inhibition Of Telomerase Is a Novel and Effective Therapy In MLL-Rearranged Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013 , 122, 2887-2887 | 2.2 | |
| 112 | Distinct Biological and Transcriptional Features Of FLT3-ITD Variants In Vitro and In Vivo. <i>Blood</i> , 2013 , 122, 481-481 | 2.2 | |
| 111 | Improving The Analysis Of Gene Expression Profiles By Comparing AML Blasts With Their Nearest Normal Counterparts. <i>Blood</i> , 2013 , 122, 2568-2568 | 2.2 | |
| 110 | Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights. <i>Seminars in Oncology</i> , 2012 , 39, 37-46 | 5.5 | 14 |

| | | | |
|-----|---|------|-----|
| 109 | High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012 , 119, e67-75 | 2.2 | 59 |
| 108 | High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 2118-26 | 2.2 | 59 |
| 107 | Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. <i>Cancer Cell</i> , 2012 , 22, 167-79 | 24.3 | 212 |
| 106 | Genetic and pharmacologic inhibition of β -catenin targets imatinib-resistant leukemia stem cells in CML. <i>Cell Stem Cell</i> , 2012 , 10, 412-24 | 18 | 185 |
| 105 | Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. <i>Blood</i> , 2012 , 119, 2314-24 | 2.2 | 128 |
| 104 | Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. <i>Cell</i> , 2012 , 148, 59-71 | 56.2 | 600 |
| 103 | Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. <i>Blood</i> , 2012 , 120, e83-92 | 2.2 | 110 |
| 102 | High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012 , 120, 4783-94 | 2.2 | 156 |
| 101 | Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression. <i>Blood</i> , 2012 , 119, 4335-7 | 2.2 | 10 |
| 100 | TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood</i> , 2012 , 119, 2114-21 | 2.2 | 411 |
| 99 | TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1350-7 | 2.2 | 166 |
| 98 | Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. <i>Blood</i> , 2012 , 120, 433-433 | 2.2 | 6 |
| 97 | The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia. <i>Blood</i> , 2012 , 120, 3522-3522 | 2.2 | |
| 96 | Inactivation of the Cell Fate Determinate Lgl1 (Lethal Giant Larvae Homolog 1) Leads to Enhanced HSC Fitness and Predicts a Poor Prognosis in AML. <i>Blood</i> , 2012 , 120, 2293-2293 | 2.2 | |
| 95 | Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2012 , 120, 3857-3857 | 2.2 | |
| 94 | Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs). <i>Blood</i> , 2012 , 120, 3592-3592 | 2.2 | |
| 93 | Microna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial. <i>Blood</i> , 2012 , 120, 2874-2874 | 2.2 | |
| 92 | Aldehyde Dehydrogenase 3a2 (Aldh3a2) Represents a Distinct Metabolic Vulnerability in MLL-AF9 AML Leukemia Initiating Cells. <i>Blood</i> , 2012 , 120, 208-208 | 2.2 | |

| | | | |
|----|--|------|-----|
| 91 | Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <i>Blood</i> , 2011 , 117, 2469-75 | 2.2 | 276 |
| 90 | AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. <i>Cell</i> , 2011 , 146, 697-708 | 56.2 | 203 |
| 89 | Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. <i>Blood</i> , 2011 , 118, 3350-8 | 2.2 | 81 |
| 88 | Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. <i>Haematologica</i> , 2011 , 96, 1783-91 | 6.6 | 36 |
| 87 | Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. <i>Blood</i> , 2011 , 117, 1329-39 | 2.2 | 81 |
| 86 | Differential niche and Wnt requirements during acute myeloid leukemia progression. <i>Blood</i> , 2011 , 118, 2849-56 | 2.2 | 118 |
| 85 | MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. <i>Cancer Cell</i> , 2011 , 20, 66-78 | 24.3 | 647 |
| 84 | High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients. <i>Blood</i> , 2011 , 118, 5613-21 | 2.2 | 25 |
| 83 | Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 51-8 | 5 | 6 |
| 82 | RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1364-72 | 2.2 | 245 |
| 81 | Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. <i>Cancer Research</i> , 2011 , 71, 4117-29 | 10.1 | 42 |
| 80 | MicroRNAs in Leukemia 2011 , 269-285 | | |
| 79 | Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 4608-4608 | 2.2 | 2 |
| 78 | Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 4997-4997 | 2.2 | 1 |
| 77 | Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples. <i>Blood</i> , 2011 , 118, 237-237 | 2.2 | |
| 76 | A Single Microarray Assay for Simultaneous Diagnosis of t(15;17), t(8;21), Inv(16)/t(16;16), NPM1 Type A/B/D Mutation, CEBPA Double Mutation, and Aberrant Expression of BAALC or EVI1 in AML/APL Patients. <i>Blood</i> , 2011 , 118, 4876-4876 | 2.2 | |
| 75 | Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations. <i>Blood</i> , 2011 , 118, 3546-3546 | 2.2 | |
| 74 | Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 236-236 | 2.2 | |

| | | | |
|----|---|------|-----|
| 73 | Myeloid Leukemogenesis Driven by Aberrant CDX2 Expression Involves Transcriptional Repression of KLF4 and Deregulated PPAR δ Signaling. <i>Blood</i> , 2011 , 118, 1355-1355 | 2.2 | |
| 72 | KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. <i>British Journal of Haematology</i> , 2010 , 148, 925-37 | 4.5 | 36 |
| 71 | Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. <i>Nature Medicine</i> , 2010 , 16, 903-8 | 50.5 | 252 |
| 70 | Prognostic impact of minimal residual disease in CBF β -MYH11-positive acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3724-9 | 2.2 | 110 |
| 69 | Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. <i>Circulation</i> , 2010 , 122, 1823-36 | 16.7 | 89 |
| 68 | IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3636-43 | 2.2 | 615 |
| 67 | Genomics in Leukemias 2010 , 421-431 | | |
| 66 | DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. <i>Future Oncology</i> , 2010 , 6, 1415-31 | 3.6 | 15 |
| 65 | High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. <i>Haematologica</i> , 2010 , 95, 666-9 | 6.6 | 40 |
| 64 | Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. <i>Blood</i> , 2010 , 115, 636-42 | 2.2 | 121 |
| 63 | HELP for AML: methylation profiling opens new avenues. <i>Cancer Cell</i> , 2010 , 17, 1-3 | 24.3 | 20 |
| 62 | SEURAT: visual analytics for the integrated analysis of microarray data. <i>BMC Medical Genomics</i> , 2010 , 3, 21 | 3.7 | 35 |
| 61 | High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. <i>Blood</i> , 2010 , 116, 849-849 | 2.2 | |
| 60 | Repressing the repressor: a new mode of MYC action in lymphomagenesis. <i>Cell Cycle</i> , 2009 , 8, 556-9 | 4.7 | 34 |
| 59 | Quantitative comparison of microarray experiments with published leukemia related gene expression signatures. <i>BMC Bioinformatics</i> , 2009 , 10, 422 | 3.6 | 27 |
| 58 | Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2009 , 83, 156-8 | 3.8 | 5 |
| 57 | Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. <i>Cell</i> , 2009 , 137, 821-34 | 56.2 | 454 |
| 56 | Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. <i>Haematologica</i> , 2009 , 94, 54-60 | 6.6 | 164 |

| | | | |
|----|---|------|------|
| 55 | Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias. <i>Blood</i> , 2009 , 113, 4690-701 | 2.2 | 13 |
| 54 | Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. <i>Blood</i> , 2009 , 113, 4505-11 | 2.2 | 142 |
| 53 | Genomics in Leukemias 2009 , 844-855 | | 1 |
| 52 | Gene Expression Profiling of the Leukemias: Oncogenesis, Drug Responsiveness, and Prediction of Clinical Outcome 2009 , 1-19 | | |
| 51 | Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 2391-2391 | 2.2 | |
| 50 | Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. <i>British Journal of Haematology</i> , 2008 , 142, 538-50 | 4.5 | 37 |
| 49 | Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. <i>Seminars in Oncology</i> , 2008 , 35, 356-64 | 5.5 | 26 |
| 48 | Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2008 , 358, 1909-18 | 59.2 | 1330 |
| 47 | Early hematopoietic zinc finger protein-zinc finger protein 521: a candidate regulator of diverse immature cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 848-54 | 5.6 | 50 |
| 46 | Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. <i>Clinical Cancer Research</i> , 2008 , 14, 7161-6 | 12.9 | 78 |
| 45 | Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. <i>Blood</i> , 2008 , 112, 1981-92 | 2.2 | 39 |
| 44 | An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. <i>Blood</i> , 2008 , 111, 4490-5 | 2.2 | 83 |
| 43 | MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. <i>Blood</i> , 2008 , 112, 4202-12 | 2.2 | 333 |
| 42 | Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. <i>Haematologica</i> , 2008 , 93, 680-7 | 6.6 | 37 |
| 41 | SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. <i>British Journal of Haematology</i> , 2008 , 140, 250-1 | 4.5 | 14 |
| 40 | Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases. <i>Blood</i> , 2008 , 112, 751-751 | 2.2 | 1 |
| 39 | Molecular and Immunological Effects of Thalidomide in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008 , 112, 2092-2092 | 2.2 | |
| 38 | High-Resolution SNP-Array Profiling Discloses Novel Genomic Aberrations in BCR/ABL-Negative Myeloproliferative Neoplasms with Myelofibrosis. <i>Blood</i> , 2008 , 112, 2794-2794 | 2.2 | |

| | | | |
|----|---|------|-----|
| 37 | Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.. <i>Blood</i> , 2008 , 112, 1487-1487 | 2.2 | |
| 36 | Distinct Expression Patterns in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Characterized by Uniparental Disomy.. <i>Blood</i> , 2008 , 112, 1193-1193 | 2.2 | |
| 35 | The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies.. <i>Blood</i> , 2008 , 112, 1524-1524 | 2.2 | |
| 34 | Common Self-Renewal Pathways Contribute to the Induction of Acute Myeloid Leukemias Associated with Different Oncogenes. <i>Blood</i> , 2008 , 112, 505-505 | 2.2 | |
| 33 | Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. <i>Haematologica</i> , 2007 , 92, 1242-5 | 6.6 | 179 |
| 32 | Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. <i>Blood</i> , 2007 , 110, 1291-300 | 2.2 | 100 |
| 31 | The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1037-48 | 15.9 | 100 |
| 30 | Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007 , 110, 3124-3124 | 2.2 | 1 |
| 29 | Combined Analysis of Valproic Acid Induced MicroRNA and Gene Expression Changes in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 869-869 | 2.2 | 1 |
| 28 | Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 3485-3485 | 2.2 | |
| 27 | KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.. <i>Blood</i> , 2007 , 110, 3163-3163 | 2.2 | |
| 26 | Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3887-94 | 2.2 | 127 |
| 25 | Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. <i>Blood</i> , 2006 , 108, 4109-17 | 2.2 | 156 |
| 24 | Characterization of NPM1-Mutated/FLT3 ITD-Negative Acute Myeloid Leukemia with Normal Karyotype by Gene Expression Profiling.. <i>Blood</i> , 2006 , 108, 155-155 | 2.2 | 1 |
| 23 | Clonal Evolution in Chronic Lymphocytic Leukemia: Acquisition of High-Risk Genomic Aberrations Associated with Unmutated VH, Resistance to Therapy, and Short Survival.. <i>Blood</i> , 2006 , 108, 296-296 | 2.2 | 1 |
| 22 | Gene Mutations as Predictive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.. <i>Blood</i> , 2006 , 108, 4-4 | 2.2 | 10 |
| 21 | A FLT3 Gene-Expression Signature Outperforms FLT3 Status in Predicting Clinical Outcome for Patients with Normal Karyotype AML.. <i>Blood</i> , 2006 , 108, 2311-2311 | 2.2 | |
| 20 | Identification of High-Level DNA Amplifications in AML with Complex Karyotype Using Array-CGH.. <i>Blood</i> , 2006 , 108, 1914-1914 | 2.2 | |

| | | | |
|----|--|------|------|
| 19 | Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.. <i>Blood</i> , 2006 , 108, 414-414 | 2.2 | |
| 18 | In Vitro and In Vivo Monitoring of Valproic Acid Effects on Gene Expression Signatures in Adult Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 2605-2605 | 2.2 | |
| 17 | Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. <i>Blood</i> , 2005 , 106, 3740-6 | 2.2 | 666 |
| 16 | Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. <i>Oncogene</i> , 2005 , 24, 6101-7 | 9.2 | 13 |
| 15 | Gene expression profiling in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6296-305 | 2.2 | 84 |
| 14 | Prognostic Gene-Expression Signatures in Adult Acute Myeloid Leukemia with Normal Karyotype.. <i>Blood</i> , 2005 , 106, 756-756 | 2.2 | |
| 13 | Array-CGH and Gene Expression Profiling Based Molecular Characterization of Myeloid Leukemia Cell Lines.. <i>Blood</i> , 2005 , 106, 4397-4397 | 2.2 | 1 |
| 12 | Gene Expression Profiling Identifies Distinct Subclasses in Core Binding Factor Acute Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 673-673 | 2.2 | |
| 11 | Genomics in myeloid leukemias: an array of possibilities. <i>Reviews in Clinical and Experimental Hematology</i> , 2005 , 9, E2 | | 1 |
| 10 | Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. <i>Haematologica</i> , 2005 , 90, 1484-92 | 6.6 | 59 |
| 9 | Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2004 , 350, 1605-16 | 59.2 | 822 |
| 8 | Drug-Response Signature Predicts Outcome in Adult Acute Myeloid Leukemia and Associates Poor Response with Molecular Characteristics of Hematopoietic Stem Cells.. <i>Blood</i> , 2004 , 104, 2024-2024 | 2.2 | |
| 7 | Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling.. <i>Blood</i> , 2004 , 104, 2037-2037 | 2.2 | |
| 6 | V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1410-1416 | 2.2 | 633 |
| 5 | t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia 2000 , 27, 285-294 | | 112 |
| 4 | BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22-p31, BCMSUN-like. <i>International Journal of Cancer</i> , 2000 , 88, 692-7 | 7.5 | 15 |
| 3 | Genomic aberrations and survival in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2000 , 343, 1910-6 | 59.2 | 2573 |
| 2 | Partitioned Learning of Deep Boltzmann Machines for SNP Data | | 1 |

| | | | |
|---|--|------|---|
| 1 | Application of precision medicine in clinical routine in haematology: Challenges and opportunities. <i>Journal of Internal Medicine</i> , | 10.8 | 1 |
|---|--|------|---|